Diligence memo · auto-generated · as of July 2, 2026

mirOculus Inc.

mirOculus Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

mirOculus Inc. operates in Biotechnology, based in SAN FRANCISCO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

mirOculus Inc. has raised $48M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $25M on 2018-08-06.

Most recent recorded round closed around 2021-02-11.

Valuation (modeled)modeled

Provath models mirOculus Inc. at approximately $616M (range $40M–$2.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.00× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 23 months.

Last raise 5.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).

Modeled value ranks above 85% of those peers.

Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.